Home›Research›Compare›Cagrilintide vs Eloralintide
Peptide ComparisonCagrilintide vs Eloralintide
Both are Metabolic peptides.
Cagrilintide
AM833
Half-life: ~7 days
21 providers listed
Eloralintide
LY3841136
Half-life: Not published
1 providers listed
Cagrilintide is carried by more providers on PeptideBase (21 vs 1); otherwise the two are closely matched on the measures we track.
Cagrilintide
Half-life
~7 days
Eloralintide
Half-life
Not published
| Your goal | Better option |
|---|---|
| Stronger clinical evidence | Cagrilintide |
| More provider options (21 vs 1) | Cagrilintide |
Research summary only — not medical advice. Consult a qualified provider before making any decisions.
Cagrilintide
Eloralintide
Cagrilintide
Novel Amylin-Based Therapies for Weight Management in Adults With Overweight or Obesity Without Diabetes: A N…
Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with o…
Combination of cagrilintide and semaglutide 2·4 mg for weight management in adults with overweight and obesit…
Cagrilintide 2·4 mg once-weekly subcutaneous injection in adults with overweight or obesity (SCALE-CAGRI): a…
+5 more
Eloralintide
Novel Amylin-Based Therapies for Weight Management in Adults With Overweight or Obesity Without Diabetes: A N…
Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of con…
Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentr…
Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to cli…
About Cagrilintide
Long-acting amylin analogue; acts on amylin/calcitonin receptors to prolong satiety; synergistic with semaglutide in CagriSema combination
About Eloralintide
Selective long-acting amylin receptor agonist; preferentially activates AMY1R over the calcitonin receptor to prolong satiety and slow gastric emptying
Information below reflects published research data only — not medical advice. Consult a qualified provider before use.
Cagrilintide
Under clinical review
Being verified by our medical team before we display contraindications for this peptide.
Given mechanistic overlap with GLP-1 agonists when used as CagriSema, monitor thyroid C-cell markers (calcitonin), lipase for pancreatitis risk, and a baseline metabolic panel. Amylin-specific monitoring guidance is evolving as Phase 3 data matures; follow prescribing protocol of the co-administered agent.
Eloralintide
Under clinical review
Being verified by our medical team before we display contraindications for this peptide.
No amylin-specific monitoring protocol is established for eloralintide, which remains investigational and is available only through clinical trials. Trial programmes track a baseline metabolic panel covering glycaemic markers, renal and hepatic function, and lipase. Calcitonin and TSH are carried over from incretin-class convention rather than from any eloralintide-specific signal, as the compound is designed for reduced calcitonin receptor activity.
Cagrilintide
Eloralintide
Not enough vendor pricing yet.
Where to source these peptides
Cagrilintide
21 listed
Browse directory →
Providers offeringEloralintide
1 listed
Browse directory →
PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.
More Metabolic Comparisons
Browse all peptides →Educational research tools — not medical advice.
Cite this page
Data last updated August 26, 2026
Free to reference and republish with attribution to PeptideBase. Choose a format:
PeptideBase. (2026). Cagrilintide vs Eloralintide — Per-mg Price Comparison. Retrieved September 11, 2026, from https://peptidebase.io/peptides/compare/cagrilintide/eloralintide